Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huang Huang, Iris To, Joana Parreira, Mei Wu, Antonia Kwan, Sarit Assouline
BACKGROUND: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. MATERIALS AND METHODS: We present interim safety data from the mosunetuzumab GO29781 (NCT02500407) phase I/II dose-escalation study in R/R non-Hodgkin lymphoma (NHL), focusing on FL. RESULTS: Overall, 218 patients with R/R NHL, including 90 with R/R FL, received a median of eight 21-day cycles of intravenous mosunetuzumab with step-up dosing in Cycle (C) 1 (C1 Day [D] 1, 1 mg; C1D8, 2 mg; C1D15/C2D1, 60 mg; C3D1 and onwards, 30 mg)...
December 12, 2023: Clinical Lymphoma, Myeloma & Leukemia